Go Deep
Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -43,419 | -0.7 | -51.65 | 0.90 | 1,922.69 |
| Oct 2026 | -43,434 | -0.7 | -51.67 | 0.90 | 1,923.91 |
| Oct 2026 | -43,279 | -0.7 | -51.40 | 0.90 | 1,908.51 |
| Oct 2026 | -44,234 | -0.7 | -51.67 | 0.90 | 1,920.98 |
| Oct 2026 | -44,572 | -0.7 | -52.29 | 0.90 | 1,943.74 |
| Oct 2026 | -42,036 | -0.7 | -47.70 | 0.90 | 1,768.69 |
| Oct 2026 | -43,290 | -0.7 | -49.97 | 0.90 | 1,849.12 |
Pelthos Therapeutics Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 15,603,000.0 | 10,906,000.0 | 9,389,000.0 | 7,406,000.0 |
| Net Profit | -23,417,000.0 | -25,073,000.0 | -21,664,000.0 | -16,238,000.0 |
| EPS | -6.6 | -3.1 | -6.9 | -5.3 |
Pelthos Therapeutics Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 16,795,000.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -43,319,000.0 | -7,955,000.0 | -7,380,793.0 | -2,458,589.0 | — |
| EPS | -23.0 | -14.3 | -12.8 | -2.6 | — |
Pelthos Therapeutics Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 130,397,000.0 | 1,369,000.0 | 96,391.0 | 55,074.0 | — |
| Total Liabilities | 91,516,000.0 | 4,083,000.0 | 6,540,943.0 | 3,761,611.0 | — |
| Total Equity | 38,881,000.0 | -2,714,000.0 | -6,444,552.0 | -3,706,537.0 | — |
Owes vs Owns
Pelthos Therapeutics Inc. owed $1.01 for every $1 it owned in Jun 2026, down from $68.3 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.01× | 0.70× | 2.98× | 67.9× | 68.3× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Pelthos Therapeutics Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 13.8%Receivables 6.8%Inventory 18.1%Fixed assets (tangible) 9.8%Intangible assets 49.2%Other assets 2.3%
How it's funded — Dec 2025
Long-term debt 24.1%Payables 2.3%Other liabilities 43.3%Shareholders' equity 29.8%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 18.0 | 0.5 | 0.1 | 0.1 |
| Receivables | 8.9 | 0.0 | 0.0 | 0.0 |
| Inventory | 23.6 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 12.8 | 0.0 | 0.0 | 0.0 |
| Intangible assets | 64.2 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 3.0 | 0.9 | 0.0 | 0.0 |
| Liabilities & equity | ||||
| Short-term debt | 0.6 | 2.2 | 1.3 | 0.5 |
| Long-term debt | 31.4 | 0.0 | 0.0 | 0.0 |
| Payables | 3.0 | 1.9 | 4.6 | 3.0 |
| Other liabilities | 56.5 | 0.0 | 0.7 | 0.2 |
| Shareholders' equity | 38.9 | -2.7 | -6.4 | -3.7 |
| Net tangible assets | -25.3 | -2.7 | -6.4 | -3.7 |
Pelthos Therapeutics Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -22,590,000.0 | -5,792,000.0 | -981,031.0 | -1,567,149.0 | — |
| Investing Activities | -5,236,000.0 | 0.0 | — | — | — |
| Financing Activities | 45,336,000.0 | 6,209,000.0 | 1,022,348.0 | 1,622,223.0 | — |